Photo of Kapil S. Meleveedu, MD

Kapil S. Meleveedu, MD

Assistant Professor of Medicine
Director, Blood and Marrow Transplantation
NPI Number:
1922353325
Academic Office Location:
Neag Comprehensive Cancer Center
UConn Health
263 Farmington Avenue
Farmington, CT 06030
Phone: 860-679-8992
860-679-2100
Website(s):

Carole and Ray Neag Comprehensive Cancer Center

Blood and Marrow Transplant and Cellular Therapy Program

  • Looking for a Physician?

    This faculty member is also
    a practicing physician at UConn Health.

    Learn more >
Education
DegreeInstitutionMajor
MBBSCalicut Medical CollegeMedicine and Surgery

Post-Graduate Training
TrainingInstitutionSpecialty
InternshipYale New Haven Health/Bridgeport HospitalInternal Medicine
ResidencyYale New Haven Health/Bridgeport HospitalInternal Medicine
FellowshipUConn School of MedicineHematology/Oncology
FellowshipMayo ClinicBlood and Marrow Transplant
  • Autologous and allogeneic blood and marrow transplant and other cellular therapies including chimeric antigen receptor therapy (CART)
  • Hematological malignancies including acute leukemias such as acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and other myeloid disorders like myeloproliferative neoplasm (MPN) and myelofibrosis (MF)
  • Bone marrow failure conditions like severe aplastic anemia (SAA), myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH)
  • Aggressive lymphomas, plasma cell disorders
Name & DescriptionCategoryRoleTypeScopeStart YearEnd Year
American Society of Hematology (ASH)Professional/Scientific OrganizationMemberExternalNational
American Society of Clinical Oncology (ASCO)Professional/Scientific OrganizationMemberExternalNational
American Society of Transplantation and Cellular therapy (ASTCT)Professional/Scientific OrganizationMemberExternalNational

Journal Articles

Book Chapters

  • Acute lymphoblastic leukemia (ALL)
    Kapil Meleveedu Ferri’s Clinical Advisor
  • Acute lymphoblastic leukemia (ALL)
    Meleveedu, Kapil Ferri’s Clinical Advisor
  • Acute myeloid leukemia (AML)
    Meleveedu, Kapil Ferri’s Clinical Advisor
  • Myelodysplastic syndrome (MDS)
    Meleveedu, Kapil Ferri’s Clinical Advisor

Abstracts

  • Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma
    Medawar G., Perez Rodriguez A., Cerio C., Todds R., Meleveedu K*. IJCCD 2022 Jun;2(Supplement 1):
  • De-Escalation of PTCy Dosing in Matched Allogenic Transplants: A Single Institution Retrospective Study
    Ackula, H., Medawar, M., Cerio, C., Roberts, TF., Meleveedu, K*. Blood 2021 Nov;138(Supplement 1):4872
  • The Cost Effectiveness of Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma – a Single Institution Experience
    Medawar, G., Rodriguez, AP., Cerio, C., Roberts, TF., Meleveedu, K*. Blood 2021 Nov;138(Supplement 1):4959
  • A Rare Manifestation of Pleural Effusion Post-Transplant Lymphoproliferative Disorder After Autologous Stem-Cell Transplant
    Salem, M., Kumar, S., Meleveedu, K Society of Hematologic Oncology (SOHO) Annual Meeting 2025
  • Assessing the adequacy of osteoporosis screening in DLBCL patients receiving R-CHOP:A single-center study
    Arunachalam J, Pile PT, Parvathy M, Meleveedu K Journal of the Endocrine Society (JES). July 2025.
  • Epidemiological and survival trends of ALK- positive large B-cell lymphoma: A SEER study.
    Arunachalam, J., Arunachalam, J., Meleveedu, K EHA Library. 06/13/2025; 4160357; PF951
  • Evaluating the comparative effectiveness of clinical trial participation on hospital outcomes among cancer patients: A trend analysis.
    Poolakkad Sankaran SK, Pili R, Panginikkod S, Meleveedu K, Epstein JB JCO 43, e23178-e23178(2025)
  • Evaluating the role of molecular markers in predicting relapse and guiding cost-effective surveillance strategies in low-grade non-Hodgkin lymphomas
    Verghese C, Meleveedu K, Bhanderi VK, Nagadia U, Raj R, Bagchi A, Ghalayini W, Koshy N JCO Oncology Practice 2025 21:10_suppl, 20-20
  • Examining TP53-mutated plasma cell disorders across the disease spectrum using broad next generation sequencing
    Ezell, K., Godin, SL., Abdallah, N., Steczko,O., Ramasamy,C., Vankina,R., Meleveedu,K., Kumar, S Blood (2025) 146 (Supplement 1): 4013
  • Immune Correlates of Response to T-Cell Engaging Bispecific Antibody Treatments in Multiple Myeloma
    Hamouche, R., Osadchyi, V., Hanna, C., Tashjian, H., Ezell, K., Godin, S.L., Meleveedu, K., Kumar, S International Myeloma Society/Clinical Lymphoma, Myeloma and Leukemia
  • Impact and disparities of COVID-19 on hematological malignancies: A database study focused on hospitalized patients in North America
    KS Meleveedu., R Pili., JB Epstein., V Satheeshkumar JCO 43, e23322-e23322(2025).
  • Improving bone marrow biopsy core length and aspirate adequacy through implementation of a powered device: A single-institution quality improvement initiative
    Chidambaram Ramasamy, Andrea Moran, Dong Chen, Swarup Kumar, Ritika Vankina, Kapil Meleveedu American Society of Hematology
  • Incidence and survival trends in mantle cell lymphoma involving tonsils: A SEER study
    Arunachalam J, Bharathi V., Kumar S., Meleveedu K Society of Hematologic Oncology (SOHO) Annual Meeting 2025. September 2025
  • Methotrexate-Induced Neurotoxicity Due to Ommaya Reservoir Malfunction in a Patient with Acute Lymphoblastic Leukemia.
    Salk G, Mangala Y, Onukogu I, Meleveedu K Clinical Lymphoma Myeloma and Leukemia.
  • Navigating Angioimmunoblastic T-Cell Lymphoma: A Diagnsotic Journey
    Godin, S.L., Ferraira, J., Hanna, C., Kumar, S., Meleveedu, K Society of Hematologic Oncology (SOHO) 13th Annual Meeting; September 3-6, 2025
  • Subclonal and Clonal Progression of Previously Characterized Mutations and Variants of Unknown Significance (VUS) Across a Cohort of Plasma Cell Dyscrasia Patients
    Ezell, K., Steczko, O., Godin, S.L., Osadchyi, V., Meleveedu, K. and Kumar, S Clinical Lymphoma, Myeloma and Leukemia, 25, p.S145.
  • Survival trends in older adults with anaplastic thyroid cancer (ATC): A SEER database study.
    Arunachalam J, Madhavan, P, Meleveedu K JCO 43, e18164-e18164(2025).
  • The Role of CHIP Mutations in Plasma Cell Dyscrasias: Implications for Clonal Evolution and Risk Stratification
    Ezell, K., Godin, S.L., Osadchyi, V., Steczko, O., Vankina, R., Meleveedu, K. and Kumar, S Clinical Lymphoma, Myeloma and Leukemia, 25, pp.S145-S146.

Case Reports

Conference Papers

  • Deferred Diagnosis: The Consequences of Excision Biopsy Deferral in Follicular Lymphoma. International Academy for Clinical Hematology (IACH) 7th Annual Meeting. Oral Session
    Godin S, El Warrack S, Chen D, Meleveedu K

Reviews

Title or AbstractTypeSponsor/EventDate/YearLocation
Cellular therapiesTalkUConn Health Cancer Center Event2023UConn Health
Overview of blood and marrow transplant and other cellular therapiesTalkInternal medicine grand rounds lecture2023UCONN Health
Blood and marrow transplant complications and role of ICU/critical careTalkPCCM grand rounds2023UCONN Health
Root cause analysis for all patients with delayed engraftment or graft failure at RWMCTalkBMT Quality meeting2022Roger Williams Medical Center. Providence, RI
The Cost Effectiveness of Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma – a Single Institution ExperienceTalkBMT Quality meeting2021Roger Williams Medical Center. Providence, RI
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaTalkImmuno-Oncology JC series2020Roger Williams Medical Center. Providence, RI
HLH with primary bone marrow lymphoma – an unusual presentationPosterACP Annual Meeting, CT chapter2014Southington, CT
Delayed occurrence of Horner’s syndrome after chest tube removalPosterACP Annual Meeting, CT chapter2014Southington, CT
Atypical hemolytic uremic syndrome – a rapidly emerging entityPosterACP Annual Meeting, CT chapter2013Southington, CT